CLINICAL_TRIALS
ClinicalTrials.gov record update
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (the NIPU-study)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04300244
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:39:56.029594+00:00
- Published At
- 2024-02-29T00:00:00+00:00
- Record Updated At
- 2024-02-29
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Cancer", "Cancer, Lung", "Cancer of Lung", "Mesothelioma", "Mesothelioma; Lung", "Mesothelioma; Pleura", "Mesotheliomas Pleural"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-02-29"- protocolSection.identificationModule.nctId
"NCT04300244"- protocolSection.identificationModule.officialTitle
"Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (the NIPU-study)"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.